Opinion|Videos|December 9, 2024
Disability Accumulation and Early Therapy: Insights from MAGNIFY-MS and High-Efficacy DMT Data
Author(s)Gabriel Pardo, MD, FAAN, Martin Belkin, DO
Key Takeaways
- Cladribine reduces disability accumulation in both treatment-naive and previously treated patients, highlighting the importance of early therapy initiation.
- High-efficacy DMTs, including ocrelizumab, ofatumumab, and S1P receptor modulators, effectively manage PIRA and mitigate disability progression.
Panelists discuss how the MAGNIFY-MS study underscores the significance of early, aggressive multiple sclerosis (MS) treatment with cladribine, demonstrating its potential to effectively mitigate disability progression through progression independent of relapse activity (PIRA) suppression in both treatment-naive and previously treated patient populations, with outcomes competitive with other high-efficacy disease-modifying therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Stefano et al presented data on disability accumulation (PIRA, relapse-associated worsening, confirmed disability accumulation) with cladribine from the MAGNIFY-MS study that show the importance of early initiation of therapy. Please highlight disability accumulation in both treatment-naive and previously treated groups.
- Please share an overview of PIRA data with other high-efficacy disease-modifying therapies (DMTs) (ocrelizumab, ofatumumab, S1P receptor modulators, etc).
Advertisement
Related to this article
The FDA accepted fenebrutinib's new drug application under priority review for relapsing and primary progressive MS, based on 3 phase 3 trials comparing the BTK inhibitor with teriflunomide and ocrelizumab.
The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.
MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Rachel Galioto, PhD. [LISTEN TIME: 33 minutes]
The positive opinion for intravenous ocrelizumab was supported by phase 3 OPERETTA 2 findings demonstrating noninferior relapse control and superior suppression of MRI-detected brain lesions compared with fingolimod in pediatric patients with relapsing MS.
An ACT–based group intervention did not significantly improve resilience at 3 months in patients with MS but was associated with improvements in anxiety, well-being, psychological flexibility, and health-related quality of life.
A phase 4 study is evaluating whether adults with chronic inflammatory demyelinating polyneuropathy can transition from intravenous immunoglobulin to subcutaneous efgartigimod PH20 without first experiencing disease worsening.
A new phase 4 trial, OCTAGON, will test a rapid, predefined corticosteroid-tapering schedule in patients with generalized myasthenia gravis treated with ravulizumab.
PETUNIA, a new global pharmacovigilance study, will track pregnancy, maternal, and infant outcomes among patients with gMG exposed to nipocalimab.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS
2
FDA Approves Tavapadon for the Treatment of Parkinson Disease
3
ADHERE REAL Study to Assess Real-World Effectiveness of Efgartigimod in CIDP
4
NeuroVoices: James Winkley, MD, on Analyzing Phase 3 PREVAIL Trial of Gefurulimab
5